https://doi.org/10.55788/8937cf82
The first-of-its-kind SuperWIN results were presented by Prof. Dylan Steen (University of Cincinnati, OH, USA) [1]. SuperWIN (NCT03895580) was a randomised-controlled dietary intervention study collaboration between academic teams and the Kroger Company, the USA’s largest supermarket chain.
Included were 247 patients from the University of Cincinnati Health Primary Care with at least 1 cardiovascular risk factor: obesity, hypertension, and/or hypercholesterolaemia. After meeting with a UC Health Primary Care physician, participants completed a medical nutrition therapy visit with a Kroger Health dietitian. Eligible participants were then randomised at their preferred supermarket into 1 of the 3 study arms: (1) standard of care plus individualised, point-of-purchase nutrition education (6 visits, ‘Strategy 1’); (2) standard of care plus individualised, point-of-purchase nutrition education enhanced with online shopping technologies and training (6 visits; ‘Strategy 2’); or (3) standard of care alone [2]. Educational sessions within each store's clinic and aisles emphasised the Dietary Approaches to Stop Hypertension (DASH) diet. The primary efficacy endpoint was the mean change in DASH score from baseline to 3 months (post-intervention). Additional outcomes included blood pressure, lipids, weight, purchasing behaviour, food literacy, and intervention feedback.
The results showed a change in DASH score from baseline to 3 months of 8.6 in the Strategy 1 group, 12.4 in the Strategy 2 group, and 5.8 in the control group (Strategies 1 and 2 vs control P= 0.02; Strategy 2 vs control P=0.01; see Table). Participants in both Strategies 1 and 2 received in-aisle advice from a Kroger Health dietitian and showed better adherence to a DASH diet than the control group. Participants in the Strategy 2 cohort, who were trained on new technologies, had an even greater adherence improvement to the DASH diet than those in other cohorts. However, no significant change was observed in the secondary endpoint of systolic blood pressure from baseline to 6 months: -6.6 with Strategy 1, -5.7 with Strategy 2, and -2.8 in the control group (Strategies 1 and 2 vs control P=0.18; Strategy 2 vs control P=0.66).
Table: 3-Month results from SuperWIN [1]
In brief, participants in either strategy arm who received in-aisle education from a Kroger Health dietitian had a greater increase in their adherence to a DASH diet than the control group. Prof. Steen concluded, “The participants were taught to shop better, right in the aisles of their home stores, based on each individual’s unique tastes and needs.”
- Steen D et al. A Multisite, Randomized, Controlled Trial Of A Supermarket And Web-based Intervention Targeting Nutrition For Cardiovascular Risk Reduction. Abstract 405–16, ACC 2022, 2–4 April, Washington DC, USA.
- Couch SC, et al. Am Heart J. 2022;248:21–34.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« AI-assisted colonoscopy improves adenoma detection Next Article
Lipoprotein(a) slashed by 98% in APOLLO trial »
« AI-assisted colonoscopy improves adenoma detection Next Article
Lipoprotein(a) slashed by 98% in APOLLO trial »
Table of Contents: ACC 2022
Featured articles
Alirocumab significantly reduces high-risk coronary plaques
Highlighted Original Research
POISE-3: Tranexamic acid for non-cardiac surgery
Treating chronic mild hypertension during pregnancy leads to better outcomes
New VOYAGER PAD data: Should patients with both PAD and CKD get rivaroxaban?
Alirocumab significantly reduces high-risk coronary plaques
Aggressive warming during non-cardiac surgery does not improve outcomes
Heart Failure and Cardiomyopathy
DIAMOND trial: Patiromer lowers risk of severe hyperkalaemia
Replacing septal reduction therapy with mavacamten for HCM
Omecamtiv mecarbil does not impact exercise capacity of patients with HFrEF
Symptomatic obstructive hypertrophic cardiomyopathy: long-term mavacamten control
Interventional and Structural Cardiology
COMPLETE revascularisation improves angina-related QoL
Plot twist for negative FAME 3 results: early QoL benefits of PCI
1-year CLASP TR results support tricuspid regurgitation repair
Head-to-head: post-TAVR edoxaban not better than DAPT
Chocolate Touch vs Lutonix catheters
No FLAVOUR difference between FFR and IVUS for PCI guidance
Myocardial Infarction
Low-resource countries benefit from global STEMI initiative
Sodium thiosulfate ineffective at cardiac protection
ICM-guided management did not improve MACE after MI
Prevention
PACIFIC-AF: Low bleeding rates for asundexian in atrial fibrillation
RCT-IVVE trial: Do HF patients benefit from annual flu shots?
TRANSLATE-TIMI 70: Primary endpoint met but safety concerns for vupanorsen
Lipoprotein(a) slashed by 98% in APOLLO trial
Dietary intervention from your supermarket
Related Articles
April 20, 2022
ACC 2022 Highlights Podcast
June 15, 2022
COMPLETE revascularisation improves angina-related QoL
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com